This Phase II open-label multicenter study evaluation of the safety and efficacy of diphtheria IL2 fusion toxin (DAB389IL-2 or DAB486IL-2) administered up to four times a year at the time of disease flare in patients with active rheumatoid arthritis was completed on June 28, 1995. Ten patients were enrolled and the data is being analyzed.
Showing the most recent 10 out of 570 publications